| SmartDyeLivery–SEVERAL: investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
| SmartDyeLivery–Thuringia (govt): investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
| DSM–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Royal DSM |
2018-10-08 |
| Lipoid–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Lipoid GmbH |
2018-10-08 |
| Sphingotec–HBM: investment, 201810 financing round totalling €20m incl co-lead investor HBM |
2018-10-08 |
| Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners |
2018-10-08 |
| Sphingotec–Wellington Partners: investment, 201810 financing round totalling €20m incl co-lead investor Wellington Partners |
2018-10-08 |
| Axcelead–ERS Genomics: CRISPR technology, 201810– license non-excl ww to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd |
2018-10-04 |
| GenAhead Bio–ERS Genomics: CRISPR technology, 201810– license non-excl to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd |
2018-10-04 |
| Sanofi–Evotec: drug discovery, 201810– collab partnership BRIDGE LAB031 for early-stage projects out of academic research |
2018-10-04 |
| Curetis–Yorkville Group: credit, 201810– up to €20m convertible notes with attached warrants to YA II PN Ltd |
2018-10-02 |
| Oncgnostics–Biotech Alliances International: business services, 201810– supply service support for global partnering + distribution strategy |
2018-10-02 |
| Roche–GO Therapeutics: antibody cancer drug, 201810– license ww excl $9m upfront/near-term +$186m milestones + royalties for bispecific antibody |
2018-10-02 |
| Sartorius–Genedata: bioinformatics, 201810 collab product integration of Genedata Bioprocess s/w with ambr mini bioreactors |
2018-10-02 |
| ATAI Life Sciences–SEVERAL: investment, 201810 1st financing round €21.2m from private investors |
2018-10-01 |
| B Braun–CeGaT: personalised medicine, 201810 collab establishment JV to develop personalised cancer vaccines CeCaVa GmbH & Co KG |
2018-10-01 |
| Forbion–SEVERAL: investment, 201810 final close €360m of Forbion IV fund |
2018-10-01 |
| Helmholtz–Bruker: MRI system, 201810 supply 9.4 Tesla preclinical MRI system with integrated PET detector to DKFZ |
2018-10-01 |
| Neuron23–SEVERAL: investment, 201810c financing round Series A $33.5m from Westlake Village BioPartners + Kleiner Perkins |
2018-10-01 |
| Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH |
2018-10-01 |
| Strüngmann Group–Cyclenium: anti-infectives, 201810– collab discovery using CMRT technology + QUEST Library with AiCuris |
2018-10-01 |
| Pfizer–Qiagen: companion diagnostics, 201809 collab existent CDx for precision medicines in onocology |
2018-09-28 |
| Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics |
2018-09-28 |
| Bayer–Genedata: bioinformatics, 201809– license to Genedata Selector s/w for Bayer CropScience division for develop new fungicides |
2018-09-27 |
| Bayer–Inova Software: business development software, 201809 supply existent Bayer is user of Inova Partnering Platform |
2018-09-27 |
| Lilly–Inova Software: business development software, 201809 supply existent Lilly is user of Inova Partnering Platform |
2018-09-27 |
| Novartis–Inova Software: business development software, 201809 supply existent Novartis is user of Inova Partnering Platform |
2018-09-27 |
| Roche–Inova Software: business development software, 201809 supply existent Roche is user of Inova Partnering Platform |
2018-09-27 |
| Genewiz–Brooks Automation: investment, 201809– acquisition $450m of Genewiz by Brooks ANNOUNCED |
2018-09-26 |
| Minoryx–SEVERAL: investment, 201809 financing round Series B €21.3m led by Fund+ with SFPI + SRIW + Sambrinvest + all Series A investors |
2018-09-26 |
| Valneva–SEVERAL: investment, 201809 private placement €50m with 13.33m new ordinary shares at €3.75/share led by US healthcare investors |
2018-09-26 |
| Aktiia–Redalpine: investment, 201809 seed financing round totalling CHF4m led by TransLink Capital + Redalpine |
2018-09-25 |
| Aktiia–SEVERAL: investment, 201809 seed financing round CHF4m led by TransLink Capital + Redalpine |
2018-09-25 |
| Aktiia–TransLink Capital: investment, 201809 seed financing round totalling CHF4m led by TransLink Capital + Redalpine |
2018-09-25 |
| Sachem–Thermo FIsher: mass spectrometer, 201809 supply existent ISQ EM single quad system early customer |
2018-09-24 |
| Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture |
2018-09-24 |
| Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners |
2018-09-24 |
| Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine |
2018-09-24 |
| Tolremo Therapeutics–SEVERAL: investment, 201809 financing round Series A CHF9m led by BioMedPartners |
2018-09-24 |
| Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB |
2018-09-24 |
| India (govt)–Thermo Fisher: mass spectrometry, 201809 collab food testing solutions using MS + chromatography with FSSAI |
2018-09-20 |
| Plug and Play–Roche: healthcare, 201809–202108 collab creation of Startup Creasphere innovation program in Munich with Roche Diagnostics |
2018-09-20 |
| Univ Salzburg–Thermo Fisher: mass spectrometry, 201809 collab biopharma characterisation with LC-MS with CDL at Univ Salzburg |
2018-09-20 |
| CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share |
2018-09-19 |
| BluCon Biotech–BRAIN: industrial biotechnology, 201809– strategic research collab microbial strain developm for PLA-based bioplastic |
2018-09-18 |
| GeNeuro–Servier: investment, 201809 existent investor Servier |
2018-09-18 |
| Almirall–Evotec: drug discovery services, 201809– collab r+d therapies for dermatological diseases |
2018-09-17 |
| BioPhero–SEVERAL: investment, 201809 seed financing round €3m from Novo Seeds + Syngenta Ventures + Syddansk Innovation |
2018-09-17 |
| Iowa State Univ–Thermo Fisher: mass spectrometry, 201809 supply existent early user of new VetDrugs Explorer Collection LC-MS/MS solution |
2018-09-17 |
| Luciole Medical–SEVERAL: investment, 201809 financing round Series A CHF5.3m (€4.7m) led by SVC Ltd (CreditSuisse) |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809 existent Qiagen owns 19.9% of NeuMoDx |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809– option to acquire remaining 80.1% of NeuMoDx for $234m |
2018-09-17 |
| Qiagen–NeuMoDx: molecular diagnostics, 201809– collab distribution outside US by Qiagen + implementation of Qiagen reagents on NeuMoDex PRC systems |
2018-09-17 |
| Coda Biotherapeutics–SEVERAL: investment, 201809 financing round Series A $19m co-led by MPM Capital + Versant Ventures |
2018-09-12 |
| Merck (DE)–AstraZeneca: digital pathology, 201809– collab multi-year partnership with Definiens using TissuePhenomics for biomarker quantification |
2018-09-10 |
| RSP Systems–SEVERAL: investment, 201809 financing round Series B 2nd closing €3.85m incl new investor Trumpf Venture GmbH |
2018-09-10 |
| RSP Systems–Trumpf: investment, 201809 financing round Series B 2nd closing totalling €3.85m incl new investor Trumpf Venture GmbH |
2018-09-10 |
| Menarini–Lunaphore: staining technology, 201809– collab Menarini Diagnostics to market LabSat Frozen tissue staining solution |
2018-09-09 |
| Celgene–Evotec: drug discovery services, 201809– strategic RnD collab in field of targeted protein degradation using Panomics platform |
2018-09-06 |
| Novartis–Aurobindo: investment, 201809 acquisition $900m cash + $100m milestones of Sandoz US dermatology + oral generics businesses by Aurobindo USA |
2018-09-06 |
| Polyphor–Novo Group: investment, 201809 capital increase CHF6.8m with 179k shares at CHF38/share sold to Novo REPAIR Impact Fund |
2018-09-06 |
| Polyphor–Novo Group: investment, 201809– project-based + royalty-bearing investment up to CHF4.7m based on milestones in OMPTA program by Novo REPAIR |
2018-09-06 |
| Twentyeight-Seven–Astellas: investment, 201809 financing round Series A totalling $65m incl co-investor Astellas Venture Management |
2018-09-06 |
| Twentyeight-Seven–JnJ: investment, 201809 financing round Series A totalling $65m incl co-investor JnJ Innovation JJDC Inc |
2018-09-06 |
| Twentyeight-Seven–Longwood Fund: investment, 201809 financing round Series A totalling $65m incl co-investor Longwood Fund |
2018-09-06 |
| Twentyeight-Seven–MPM Capital: investment, 201809 financing round Series A totalling $65m incl founding + co-lead investor MPM Capital |
2018-09-06 |
| Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF |
2018-09-06 |
| Twentyeight-Seven–SEVERAL: investment, 201809 financing round Series A $65m co-led by founding investor MPM Capital + NVF |
2018-09-06 |
| Twentyeight-Seven–Temasek: investment, 201809 financing round Series A totalling $65m incl co-investor Vertex Ventures HC |
2018-09-06 |
| Creoptix–Waters: investment, 201809 investment by new investor Waters Corp |
2018-09-05 |
| Miracor–SEVERAL: investment, 201809 financing round Series D totalling €30m final closing led by Ming Capital (CN) |
2018-09-04 |
| Mologen–SEVERAL: investment, 201809 capital increase €8.2m with 1.73m new shares at €4.7/share to existing + new investors |
2018-09-03 |
| CHDI–Evotec: drug discovery services, 201808–2023 collab service extension CDHI funding up to 75 full-time scientists for Huntington’s disease drugs |
2018-08-30 |
| Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors |
2018-08-30 |
| Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs |
2018-08-29 |
| Nebula Genomics–SEVERAL: investment, 201808 seed financing round $4.3m from ten leading tech + biotech VCs |
2018-08-29 |
| PhagoMed–Austria (govt): grant, 201808–2021 research project grant €3.5m from FFG |
2018-08-28 |
| PhagoMed–Austria (govt): investment, 201808 seed financing round totalling €1.55m incl €800k aws-Seedfinancing |
2018-08-28 |
| PhagoMed–OTHER: investment, 201808 seed financing round totalling €1.55m incl €750k from private investors |
2018-08-28 |
| PhagoMed–SEVERAL: investment, 201808 seed financing round €1.55m from private investors + aws |
2018-08-28 |
| Evotec–Centogene: drug discovery, 201808– collab ww strategic €na discovery + developm of treatments for rare genetic diseases |
2018-08-27 |
| Proteomedix–Altos Venture: investment, 201808 financing round totalling CHF5.2m incl exising + lead investor Altos Venture |
2018-08-27 |
| Proteomedix–SEVERAL: investment, 201808 financing round CHF5.2m from exising investors led by Altos Venture + incl ZKB |
2018-08-27 |
| Proteomedix–Zürcher Kantonalbank: investment, 201808 financing round totalling CHF5.2m incl exising + co-investor ZKB |
2018-08-27 |
| Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech |
2018-08-27 |
| Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata |
2018-08-27 |
| Univ Wisconsin–Thermo Fisher: FAIMS technology, 201808 supply use of FAIMS device for shotgun proteomics by Joshua Coon |
2018-08-27 |
| Hain Lifescience–Bruker: investment, 201808– acquisition €na of 80% majority interest with option to acquire rest in 2012 ANNOUNCED |
2018-08-24 |
| c-LEcta–Capricorn Venture Partners: investment, 201808 financing round incl new + lead investor Capricorn investing via CSCF NV + Quest for Growth |
2018-08-23 |
| c-LEcta–SEVERAL: investment, 201808 financing round €na with new investors Capricorn Venture Partners + bm|t |
2018-08-23 |
| c-LEcta–Thuringia (govt): investment, 201808 financing round incl new + co-investor bm|t via MFT Mittelstands-Fonds Thüringen |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201804 financing round CHF4.44m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201808 financing round CHF6m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Merck (DE)–GlucoMe: digital health, 201808– collab digital diabetes management project in Vietnam |
2018-08-22 |
| Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance r+d small molecule drugs for diabetes + obesity Novo Nordisk |
2018-08-22 |
| SolasCure–BRAIN: investment, 201808 financing round Series A with participation of BRAIN at spin-off of SolasCure from BRAIN |
2018-08-22 |
| SolasCure–BRAIN: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure |
2018-08-22 |
| SolasCure–SEVERAL: investment, 201808 financing round Series A with participation of BRAIN |
2018-08-22 |
| NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan |
2018-08-16 |
| Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 |
2018-08-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 14 15 16 ... 30 31 32 
Date![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
